Over nearly three decades, Danish researchers have watched a quiet but consequential shift unfold: people living with type 2 diabetes are developing cancer at accelerating rates, and the distance between them and the general population continues to grow. A study drawing on the health records of more than 710,000 people — to be presented at a major European diabetes conference — finds that cancer has now become the leading cause of death among diabetics in wealthy nations, surpassing the cardiovascular and kidney complications that have long defined the disease's shadow. The findings invite med
Cancer incidence accelerates among type 2 diabetes patients, study finds
Cancer has become the leading cause of death among people with type 2 diabetes in Denmark and other high-income countries, affecting millions with increased mortality risk.
Cancer has become the leading cause of death among diabetics in high-income countries.
Mark
So cancer is now the leading cause of death for people with type 2 diabetes in Denmark. That's a significant shift, isn't it?
Mimi
It is. For decades, the focus in diabetes care has been on preventing heart attacks and kidney failure—and those interventions have worked. But as people live longer with better cardiovascular protection, cancer has moved into the foreground.
Luke
But we should be careful here. The study shows cancer is the leading cause of death among diabetics in Denmark and some other high-income countries. We don't know if that's true globally, or if it reflects better survival from other causes rather than more cancer itself.
Mark
The numbers show cancer incidence is rising faster in the diabetes group than in the general population. What's driving that?
Mimi
The study points to obesity-related cancers—colorectal, breast, and others. The gap for those cancers has widened significantly over 25 years. But the researchers are honest that they can't isolate whether it's diabetes itself, obesity, or some combination.
Luke
Right. And they explicitly say they didn't measure weight, smoking, or physical activity. So we're seeing an association, not a causal chain. The lung cancer finding is interesting though—it flipped in women from lower to higher incidence.
Mark
Why would that happen?
Mimi
The study doesn't explain it. That's the kind of pattern that raises questions for future research. It suggests something changed in the relationship between diabetes and lung cancer risk in women over those 25 years.
Luke
Or something changed in how women with diabetes are screened, diagnosed, or treated. We can't tell from this data.
Mark
What's the practical takeaway for someone with type 2 diabetes?
Mimi
The researchers are calling for cancer screening to be integrated into routine diabetes care—making sure people with diabetes actually use colorectal and breast cancer screening programs that already exist.
Luke
Which is reasonable, but it assumes screening access is equal, which it often isn't. The study is Danish data from a universal healthcare system. The applicability elsewhere is an open question.
Le Pouls
- Cancer incidence among people with type 2 diabetes is rising faster than in the general population — men are now 12% more likely to develop cancer, women 22% more likely, and both gaps have widened measurably over the past decade.
- Obesity-related cancers are driving the steepest acceleration, with colorectal and postmenopausal breast cancer showing some of the sharpest increases, while lung cancer in women with diabetes reversed from being less common to 25% more common in just over a decade.
- The pattern is not uniform — prostate cancer is actually less frequent in men with diabetes, signaling that the relationship between metabolic disease and cancer is complex, not simply additive.
- Cancer has overtaken cardiovascular disease as the leading killer of people with type 2 diabetes in Denmark and other high-income countries, a shift that reflects both better heart and kidney care and a growing, under-addressed oncological burden.
- Researchers are calling for cancer screening and prevention to be formally integrated into diabetes care protocols, particularly for colorectal and breast cancer, where screening tools already exist but participation among diabetics lags.
Over nearly three decades, Danish researchers have watched a quiet but consequential shift unfold: people living with type 2 diabetes are developing cancer at accelerating rates, and the distance between them and the general population continues to grow. A study drawing on the health records of more than 710,000 people — to be presented at a major European diabetes conference — finds that cancer has now become the leading cause of death among diabetics in wealthy nations, surpassing the cardiovascular and kidney complications that have long defined the disease's shadow. The findings invite medicine to reckon with an uncomfortable possibility: that in successfully extending the lives of people with diabetes, we may have inadvertently lengthened their exposure to a different, less-managed threat.
A research team at Steno Diabetes Center Aarhus spent nearly three decades following the health records of Denmark's entire adult population — more than 710,000 people — and what they found was not a stable picture but a worsening one. People with type 2 diabetes are developing cancer at rates that are not only higher than the general population, but growing more divergent over time. The findings are set to be presented at the European Association for the Study of Diabetes conference in Milan.
Between 2010 and 2022, men with type 2 diabetes had a 12 percent higher cancer incidence than men without the condition; women faced a 22 percent higher rate. A decade earlier, those figures stood at 9 and 15 percent respectively. The acceleration is most visible in obesity-related cancers: among men with diabetes, these occurred 45 percent more frequently than in men without diabetes, up from 34 percent in the earlier period. Colorectal cancer was 17 percent more common in men with diabetes and 14 percent more common in women. Postmenopausal breast cancer was 8 percent more frequent in women with the condition.
Not every cancer follows the same pattern. Prostate cancer — the most common cancer in men — appeared 19 percent less often in men with type 2 diabetes. Lung cancer told a more unsettling story, particularly for women: where it had once been 12 percent less common in women with diabetes, it became 25 percent more common by the study's final years, a reversal that researchers flagged as especially striking.
Dr. Tinne Laurberg, who led the study, noted that cancer has now become the leading cause of death among people with type 2 diabetes in Denmark and comparable nations — a shift that reflects both the success of modern diabetes care in reducing cardiovascular and kidney deaths, and the growing weight of an oncological threat that has not been equally addressed. She called for cancer screening and prevention to be woven into the standard long-term management of diabetes, especially for cancers where programs already exist.
The researchers were deliberate about the limits of their findings. The study documents a population-level trend — it does not prove that diabetes causes cancer, nor does it disentangle the roles of weight, smoking, or physical activity. What it does establish, across 27 years and hundreds of thousands of lives, is a signal that is growing louder and that diabetes medicine can no longer afford to treat as peripheral.
Researchers tracking the health records of Denmark's entire adult population over nearly three decades have documented a troubling shift: people living with type 2 diabetes are developing cancer at accelerating rates, and the gap between them and those without diabetes is widening. The findings, set to be presented this week at the European Association for the Study of Diabetes conference in Milan, suggest that cancer prevention may need to become as central to diabetes care as the management of heart and kidney disease has long been.
The study examined 27 years of data, from 1996 through 2022, tracking more than 710,000 Danes—both those with type 2 diabetes and those without. Over that span, researchers identified 75,540 first cancers among people with diabetes and 635,323 among those without. When the numbers are adjusted for population differences, the picture becomes stark: in the most recent period studied (2010 to 2022), men with type 2 diabetes had a 12 percent higher cancer incidence than men without diabetes, while women with type 2 diabetes faced a 22 percent higher rate. A decade earlier, those gaps had been smaller—9 percent for men and 15 percent for women. The trend is moving in the wrong direction.
The acceleration is most pronounced in cancers linked to obesity. Among men with type 2 diabetes, obesity-related cancers occurred 45 percent more frequently than in men without diabetes during 2010 to 2022, up from a 34 percent difference in the earlier period. For women, the increase was from 23 percent to 30 percent. Colorectal cancer, the third most common cancer overall, showed a 17 percent higher incidence in men with diabetes and 14 percent higher in women. Postmenopausal breast cancer, the most common cancer among women, was 8 percent more common in women with type 2 diabetes.
But the relationship between diabetes and cancer is not uniform across all tumor types. Prostate cancer, the most common cancer in men, actually appeared 19 percent less frequently in men with type 2 diabetes than in men without it. Lung cancer presented a more complex picture: it was 23 percent higher in men with diabetes and 25 percent higher in women with diabetes during 2010 to 2022. What makes this striking is the reversal in women—lung cancer incidence was 12 percent lower in women with diabetes in the earlier period, then jumped to 25 percent higher by the most recent years.
Dr. Tinne Laurberg, who led the research at Steno Diabetes Center Aarhus, emphasized that cancer has now become the leading cause of death among people with type 2 diabetes in Denmark and other wealthy nations. That shift reflects both improvements in managing cardiovascular and kidney complications—the traditional focus of diabetes care—and the growing toll of cancer. Laurberg called for integrating cancer screening and prevention into the standard long-term management of diabetes, particularly for cancers where screening programs already exist, such as colorectal and breast cancer. The challenge, she noted, is ensuring that people with diabetes actually participate in these programs at rates comparable to the general population.
The researchers were careful to note what their study does not prove. They documented differences in cancer incidence between people with and without diabetes, but they did not establish whether diabetes itself causes cancer or whether other factors—weight, smoking, physical activity, alcohol use—explain the association. Those questions remain open. The study also clarifies that calling a cancer "obesity-related" reflects a known statistical association at the population level, not proof that obesity alone accounts for the higher rates observed in the diabetes group. What the data does show is a population-level trend that has grown more pronounced over a quarter century, and a public health signal that warrants attention as diabetes care evolves.
Citations marquantes
Cancer prevention and early detection must be prioritized as part of long-term diabetes care, especially for common obesity-related cancers like colorectal and postmenopausal breast cancer.— Dr. Tinne Laurberg, Steno Diabetes Center Aarhus
As outcomes for cardiovascular and kidney disease improve, cancer may require greater attention in the long-term care of people with type 2 diabetes.— Dr. Tinne Laurberg
Envie de l'histoire complète ?
Lire l'original sur News-Medical ↗
Health & Medicine